반응식
[CH:1]1([C:4]2[C:5]([O:13][C@@H:14]([CH3:19])[C:15]([F:18])([F:17])[F:16])=[CH:6][C:7]([C:10]([OH:12])=O)=[N:8][CH:9]=2)[CH2:3][CH2:2]1.[CH3:20][C:21]1[O:25][C:24]([C:26]([NH2:33])([CH3:32])[CH2:27][CH:28]2[CH2:31][O:30][CH2:29]2)=[N:23][N:22]=1>>[CH:1]1([C:4]2[C:5]([O:13][C@@H:14]([CH3:19])[C:15]([F:18])([F:17])[F:16])=[CH:6][C:7]([C:10]([NH:33][C:26]([C:24]3[O:25][C:21]([CH3:20])=[N:22][N:23]=3)([CH3:32])[CH2:27][CH:28]3[CH2:31][O:30][CH2:29]3)=[O:12])=[N:8][CH:9]=2)[CH2:2][CH2:3]1참가 물질
3
반응물 2
생성물 1
실험 절차
The title compound was synthesized in analogy to Example 112e, using 5-Cyclopropyl-4-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-pyridine-2-carboxylic acid (Example 68a) and 2-(5-methyl-1,3,4-oxadiazol-2-yl)-1-(oxetan-3-yl)propan-2-amine (example 190c) as starting materials and isolated (36 mg, 22%); MS (ESI, m/z): 441.5 (M+H+).
후처리
- customisolated (36 mg, 22%)
출처 및 근거
- ORD 기록
- ord-550a73d72c8e4c0a83affe01dc60a16a
- 출처 데이터셋
- uspto-grants-2016_08
- 특허 번호
- US09409866B2
연결된 노트
불러오는 중…